Pursuant to RSA 328-E:16, III, the formulary for licensees shall be as follows:
(a) Amino acids and peptides, including but not limited to:
6) Succinic Acid (DMSA); and
(b) Animal preparations and their derivatives, including but not limited to:
(4) Fish oils, including derived mega-3 fatty acids such as Ethyl eicosapentaenoic acid, docosahexaenoic acid, and omega-3 carboxylic acids;
(6) Bile acids, including deoxycholic acid;
(c) The following anti-gout agents:
(d) H
1 and H
2 antihistamine-class agents;
(e) The following anti-leukotriene agents:
(f) The following anti-hyperglycemic agents:
(1) The alpha glucosidase inhibitor Acarbose;
(2) The biguanide Metformin;
(3) Sulfonylurea-class agents;
(4) Thiazolidinedione-class agents (TZDs);
(5) Sodium-glucose transport protein 2 (SGLT-2) inhibitors;
(6) Dipeptidyl peptidase 4 (DPP-4) inhibitors;
(7) Glucagon-like peptide-1 (GLP-1) receptor agonists; and
(8) Synthetic and human insulin;
(g) The following anti-infective agents:
(1) The following antibacterial agents:
a. Aminoglycosides, including but not limited to:
2. Kanamycin sulfate; and
b. The following beta-lactam antibiotics:
1. Cephalosporins, including but not limited to:
(viii) Cepodoxime proxetil;
2. Penicillins, including but not limited to:
(i) Amoxicillin and clavulanate;
(iii) Ampicillin and sulbactam;
c. Macrolides and ketolides, including but not limited to:
d. Quinolones, including but not limited to:
e. The following sulfonamides:
f. Tetracyclines, including but not limited to:
1. Demeclocycline hydrochloride;
g. The following miscellaneous antibacterials:
(2) Antifungals, such as:
(3) The following anti-virals:
(4) Anti-helmetics, such as:
(5) The following antitubercular and antimycobacterial agents:
(6) The following antiprotozoal and antiparasitic agents:
a. The halogenated 8-hydroxyquinoline iodoquinol;
b. The following nitroimidazoles:
c. The following quinolines:
d. The hydroxynaphthoquinone atovaquone; and
(7) The following miscellaneous anti-infective agents:
(h) The following anti-thyroid agent thionamides (thioureylenes) :
(i) The following autonomic agents:
(1) The following cholinergic agents:
a. The following antimuscarinic agents:
5. Homatropine hydrobromide;
b. The muscarinic receptor agonist pilocarpine;
c. Nicotinic receptor agonists:
d. The following acetylcholinesterase inhibitors:
(2) The following ergot derivatives:
a. Ergonovine maleate; and
(3) The following sympathomimetics:
b. Epinephrine, including autoinject forms;
(4) The following sympatholytic agents:
a. The following alpha adrenergic blocking agents:
b. Beta adrenergic blocking agents, including but not limited to:
(5) The following agents for ADHD/Narcolepsy treatment:
c. Amphetamine/dextroamphetamine;
(j) The following biologicals:
(1) The following biological response modifiers:
a. Candida and tricophyton extracts; and
b. Rho(D) immune globulins;
(2) The following skin test antigens:
a. Purified protein derivative tuberculin tests;
b. Candida albicans skin test antigen; and
c. Coccidioides immitis spherule derived skin test antigen;
(4) Blood and tissue derived products;
(5) Enzymes, including but not limited to:
(6) Electrolytes and fluid replacements, including but not limited to:
d. Lactated ringers solution; and
(7) Hormones as described in Nat 406.01(p);
(9) Prostaglandins and prostaglandin analogs, including but not limited to:
(10) Botolinum toxin derivatives:
b. Abobotulinumtoxin A; and
(k) Botanical preparations, with the following exceptions::
(1) Legend or controlled Digitalis species derivatives;
(2) Legend or controlled Coca species derivatives;
(3) Legend or controlled Vinca species derivatives;
(4) Legend or controlled Taxus species derivatives;
(5) Legend or controlled Rauwolfia species derivatives; and
(6) Derivatives of Papaver somniferum unless otherwise specified;
(l) The following cardiovascular agents:
(1) The following antilipemics:
a. HMG CoA reductase inhibitors, such as:
(2) The following anti-angina, piperazine derivative, metabolism modifiers, or p-FOX inhibitors;
(3) The following anti-angina nitrates:
b. Isosorbide dinatrate; and
c. Isosobide mononitrate;
(4) Dihydropyridine-class calcium channel blockers;
(5) The following non-dihydropyridine calcium channel blockers:
(6) Angotensin converting enzyme inhibitors;
(7) Angiotensin II receptor blockers;
(8) The following diuretics:
(9) The following anti-coagulant agents:
a. Heparin for in-office use;
(m) The following central nervous system agents:
(1) The following anticonvulsant and antipeptic agents:
(2) The following antispasmodics:
(3) The following anxiolytics, sedatives and hypnotics:
1. The following benzodiazepines;
2. The following non-benzodiazepine sedative-hypnotic agents:
a. The imidazopyridine agent Zolpidem;
b. The cyclopyrrolone agent Eszopiclone;
3. The anti-manic agent Lithium; and
4. The anxiolytic Buspirone; and
(4) Antidepressants for FDA approved age groups:
a. The following selective serotonin reuptake inhibitors (SSRIs):
b. Serotonin-norepinephirene reuptake inhibitors (SNRIs):
c. The following tricyclic antidepressants (TCAs):
(n) The following erectile dysfunction agents:
(o) Homeopathic preparations and their derivatives including both sterile injectable and non-injectable dosage forms;
(p) Hormones such as:
(1) Adrenal hormones, such as:
e. Synthetic glucocorticoids such as:
4. Triamcinolone and Triamcinolone acetonide;
5. Methylprednisolone and Prednisolone;
(2) Selective estrogen-receptor modulators (SERMs), and anti-estrogens or estrogen antagonists, such as:
(3) Gonadal hormones, such as:
(4) Thyroid hormones, such as:
c. Natural dessicated thyroid hormones; and
(5) Pituitary hormones, such as:
(6) Hormonal modifiers, such as:
(q) Antitussives, such as:
(r) Local anesthetics, including both injectable and non-injectable dosage form such as:
(1) Amino esters for in-office use:
(2) Amino amides, for in-office use:
(3) The following other topical anesthetics:
a. The ketone Dyclonine, for in-office use;
c. The skin refrigerant ethyl chloride, also known as chloroethane; and
d. Topical lidocaine; and
(4) The methyl group donor betaine;
(s) Anti-psoriatic agents for topical use only:
(1) Dithranol (anthralin);
(t) Minerals, trace minerals, and their derivatives, such as super saturated potassium iodine (SSKI);
(u) The following miscellaneous agents:
(8) Ethyl Chloride spray;
(10) Fluro-methane spray;
(13) Methylsulfonylmethane;
(17) Poly-L-lactic acid and derivatives;
(18) Salicylates, propionic acid, and acetic acid derivatives such as:
b. Topical salicyclic acid preparations;
(v) In-office medical equipment, medical devices, and therapeutic devices such as:
(5) The following barrier contraceptives:
b. Diaphragms, excluding intrauterine devices;
(6) Nebulizers, inhalers, spacers, actuators, and mouthpieces for medication delivery;
(7) CPAP machies and medical devices for the treatment and prevention of sleep apnea; and
(w) Agents needed to carry out diagnostic tests or physiological function tests such as:
(4) Dyes and contrasts such as:
(x) Vaccinations, provided they are for use and not prescription, including but not limited to:
(5) Haemophilus b Conjugate;
(9) Japanese Encaphalitis Virus;
(15) Polio virus - inactivated;
(16) Poliovirus - live oral;
(y) All forms of prescription and non-prescription vitamin preparations and their derivatives, except for Isotretinoin; and
(z) Anti-addictive agents:
N.H. Code Admin. R. Nat 406.01
#8679, eff 7-11-06; ss by #9656, eff 2-13-10
Amended by Volume XXXVII Number 23, Filed June 8, 2017, Proposed by #12176, Effective 5/17/2017, Expires 5/17/2027.
Amended by Volume XL Number 41, Filed October 8, 2020, Proposed by # 13112, Effective 9/24/2020, Expires 9/24/2030.